Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody
- 01.06.2013
- case report
Erschienen in:
- Verfasst von
- Cathrin Skrabs
- Christian Sillaber
- Ana-Iris Schiefer
- Ingrid Simonitsch-Klupp
- Thomas Staudinger
- Monique Putman
- Werner Rabitsch
- Ulrich Jaeger
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 2/2013
Abstract
Background
Patients with follicular lymphoma ineligible for standard treatment with the anti-CD20 antibody rituximab represent a considerable challenge as they require alternative therapeutic approaches.
Patient and methods
We describe a patient who experienced a severe episode of serum sickness. Antichimeric antibodies against rituximab were verified in an early stage of disease, rendering further use of the drug impossible. After five treatment lines he developed progressive follicular lymphoma with skin involvement, which was treated with lenalidomide monotherapy.
Results
Six cycles of lenalidomide monotherapy (25 mg orally for 21 days, 1 week off) led to a very good partial response rendering the patient eligible for autologous stem cell transplantation. Data on efficacy of lenalidomide in follicular lymphoma are reviewed.
Conclusion
As shown here, single-agent lenalidomide represent a therapeutic option for pretreated patients with follicular lymphoma ineligible for rituximab.
Anzeige
- Titel
- Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody
- Verfasst von
-
Cathrin Skrabs
Christian Sillaber
Ana-Iris Schiefer
Ingrid Simonitsch-Klupp
Thomas Staudinger
Monique Putman
Werner Rabitsch
Ulrich Jaeger
- Publikationsdatum
- 01.06.2013
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-013-0089-5
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.